Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor

Journal of Clinical Investigation

Volumn 115, Issue 12, 2005, Pages 3613-3622

  Chutipongtanate, Somchai ^a   Nakagawa, Yasushi ^b   Sritippayawan, Suchai ^c   Pittayamateekul, Jeeraporn ^a   Parichatikanond, Paisal ^a   Westley, Bruce R ^d   May, Felicity E B ^d   Malasit, Prida ^a,e,f   Thongboonkerd, Visith ^a,f  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANION; ANTIBODY; CALCIUM ION; CALCIUM OXALATE; GLUTAMIC ACID; PROTEIN; PROTEIN INHIBITOR; PROTEIN NEPHROCALCIN; TREFOIL FACTOR 1; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ADSORPTION; ADULT; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; ELECTROSPRAY; FEMALE; GEL FILTRATION; HUMAN; ION TRAP MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEPHROLITHIASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; URINALYSIS; WESTERN BLOTTING;

ADULT; AGED; AMINO ACID SEQUENCE; ANIONS; BINDING SITES; BLOTTING, WESTERN; CALCIUM OXALATE; CELLULOSE; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; COHORT STUDIES; CRYSTALLIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IONS; KIDNEY CALCULI; KINETICS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SEX FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 31044450826     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25342     Document Type: Article

References (49)

1. Ramello, A., Vitale, C., and Marangella, M. 2000. Epidemiology of nephrolithiasis. J. Nephrol. 13(Suppl. 3):S45-S50.
2. Coe, F.L., Parks, J.H., and Asplin, J.R. 1992. The pathogenesis and treatment of kidney stones. N. Engl. J. Med. 327:1141-1152.
3. Lieske, J.C., and Deganello, S. 1999. Nucleation, adhesion, and internalization of calcium-containing urinary crystals by renal cells. J. Am. Soc. Nephrol. 10(Suppl. 14):S422-S429.
4. Parks, J.H., Coward, M., and Coe, F.L. 1997. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 51:894-900.
5. Mandel, N. 1996. Mechanism of stone formation. Semin. Nephrol. 16:364-374.
6. Kok, D.J., Papapoulos, S.E., and Bijvoet, O.L. 1990. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int. 37:51-56.
7. Lieske, J.C., Swift, H., Martin, T., Patterson, B., and Toback, F.G. 1994. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. Proc. Natl. Acad. Sci. U. S. A. 91:6987-6991.
8. Lieske, J.C., Deganello, S., and Toback, F.G. 1999. Cell-crystal interactions and kidney stone formation. Nephron. 81(Suppl. 1):8-17.
9. Finlayson, B., and Reid, F. 1978. The expectation of free and fixed particles in urinary stone disease. Invest. Urol. 15:442-448.
10. Kok, D.J., and Khan, S.R. 1994. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int. 46:847-854.
11. Ryall, R.L. 1996. Glycosaminoglycans, proteins, and stone formation: adult themes and child's play. Pediatr. Nephrol. 10:656-666.
12. Coe, F.L., Nakagawa, Y., Asplin, J., and Parks, J.H. 1994. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner. Electrolyte Metab. 20:378-384.
13. Wesson, J.A., et al. 2003. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol. 14:139-147.
14. Hess, B. 1994. Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner. Electrolyte Metab. 20:393-398.
15. Randall, A. 1937. The origin and growth of renal calculi. Ann. Surg. 105:1009-1027.
16. Low, R.K., and Stoller, M.L. 1997. Endoscopic mapping of renal papillae for Randall's plaques in patients with urinary stone disease. J. Urol. 158:2062-2064.
17. Evan, A.P., et al. 2003. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 111:607-616. doi:10.1172/JCI200317038.
18. Bushinsky, D.A. 2003. Nephrolithiasis: site of the initial solid phase. J. Clin. Invest. 111:602-605. doi:10.1172/JCI200318016.
19. Evan, A.P., et al. 2005. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 67:576-591.
20. Pak, C.Y., Poindexter, J.R., Peterson, R.D., and Heller, H.J. 2004. Biochemical and physicochemical presentations of patients with brushite stones. J. Urol. 171:1046-1049.
21. Pak, C.Y. 1969. Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J. Clin. Invest. 48:1914-1922.
22. Nakagawa, Y., Ahmed, M., Hall, S.L., Deganello, S., and Coe, F.L. 1987. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in γ-carboxyglutamic acid. J. Clin. Invest. 79:1782-1787.
23. Hess, B. 1992. Tamm-Horsfall glycoprotein - inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol. Res. 20:83-86.
24. Shiraga, H., et al. 1992. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc. Natl. Acad. Sci. U. S. A. 89:426-430.
25. Atmani, F., and Khan, S.R. 1999. Role of urinary bikunin in the inhibition of calcium oxalate crystallization. J. Am. Soc. Nephrol. 10(Suppl. 14):S385-S388.
26. Ryall, R.L., et al. 1995. The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin. Sci. (Lond.). 89:533-541.
27. Han, I.S., et al. 2002. FKBP-12 exhibits an inhibitory activity on calcium oxalate crystal growth in vitro. J. Korean Med. Sci. 17:41-48.
28. Tsujihata, M., et al. 2000. Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. J. Urol. 164:1718-1723.
29. Selvam, R., and Kalaiselvi, P. 2000. A novel basic protein from human kidney which inhibits calcium oxalate crystal growth. BJU Int. 86:7-13.
30. Chadwick, M.P., Westley, B.R., and May, F.E.B. 1997. Homodimerization and hetero-oligomerization of the single-domain trefoil protein pNR-2/pS2 through cysteine 58. Biochem. J. 327:117-123.
31. Nakagawa, Y., Kaiser, E.T., and Coe, F.L. 1978. Isolation and characterization of calcium oxalate crystal growth inhibitors from human urine. Biochem. Biophys. Res. Commun. 84:1038-1044.
32. Nakagawa, Y., et al. 1985. Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J. Clin. Invest. 76:1455-1462.
33. Worcester, E.M., Nakagawa, Y., Wabner, C.L., Kumar, S., and Coe, F.L. 1988. Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am. J. Physiol. 255:F1197-F1205.
34. Chenard, M.P., Tomasetto, C., Bellocq, J.P., and Rio, M.C. 2004. Urinary pS2/TFF1 levels in the management of hormonodependent breast carcinomas. Peptides. 25:737-743.
35. Zerwekh, J.E., Holt, K., and Pak, C.Y. 1983. Natural urinary macromolecular inhibitors: attenuation of inhibitory activity by urate salts. Kidney Int. 23:838-841.
36. Coe, F.I., Parks, J.H., and Nakagawa, Y. 1991. Protein inhibitors of crystallization. Semin. Nephrol. 11:98-109.
37. Nakagawa, Y., Abram, V., Kezdy, F.J., Kaiser, E.T., and Coe, F.L. 1983. Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J. Biol. Chem. 258:12594-12600.
38. Sorensen, S., Justesen, S.J., and Johnsen, A.H. 1995. Identification of a macromolecular crystal growth inhibitor in human urine as osteopontin. Urol. Res. 23:327-334.
39. Masiakowski, P., et al. 1982. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10:7895-7903.
40. May, F.E.B., and Westley, B.R. 1986. Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res. 46:6034-6040.
41. Jakowlew, S.B., Breathnach, R., Jeltsch, J.M., Masiakowski, P., and Chambon, P. 1984. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res. 12:2861-2878.
42. Rio, M.C., et al. 1988. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science. 241:705-708.
43. Piggott, N.H., Henry, J.A., May, F.E.B., and Westley, B.R. 1991. Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. J. Pathol. 163:95-104.
44. Ribieras, S., Tomasetto, C., and Rio, M.C. 1998. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim. Biophys. Acta. 1378:F61-F77.
45. May, F.E.B., and Westley, B.R. 1997. Trefoil proteins: their role in normal and malignant cells. J. Pathol. 183:4-7.
46. Miyashita, S., Nomoto, H., Konishi, H., and Hayashi, K. 1994. Estimation of pS2 protein level in human body fluids by a sensitive two-site enzyme immunoassay. Clin. Chim. Acta. 228:71-81.
47. Marchbank, T., Westley, B.R., May, F.E.B., Calnan, D.P., and Playford, R.J. 1998. Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. J. Pathol. 185:153-158.
48. Polshakov, V.I., et al. 1997. High-resolution solution structure of human pNR-2/pS2: a single trefoil motif protein. J. Mol. Biol. 267:418-432.
49. Williams, M.A., Westley, B.R., May, F.E.B., and Feeney, J. 2001. The solution structure of the disulphide-linked homodimer of the human trefoil protein TFF1. FEBS Lett. 493:70-74.